{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:13:19Z","timestamp":1753877599064,"version":"3.41.2"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hepatitis delta (HDV) infection is either acquired simultaneously with, or as a superinfection to, existing Hepatitis B (HBV). It leads to a serious form of chronic viral hepatitis and accelerated liver-related morbidity and mortality including hepatocellular carcinoma. Current treatment regimes propose Pegylated interferon-alpha for 48\u00a0weeks however sustained virological response (SVR) rates remain low. We report a patient who initially responded to Pegylated interferon treatment for HBV-HDV co-infection. Although initial improvement in viraemia from both virsues was seen, SVR was not achieved with ongoing progression of liver injury biochemically. However, the summative effect of a second course of Pegylated interferon 2\u00a0years later led to HDV cure (SVR 12\u00a0months post-treatment), very low level HBV carrier status (with persistently undetectable viral load) and ongoing biochemical normalization. This case illustrates a successful treatment strategy for persistent HBV-HDV co-infection where proposed treatment regimes elicit an initial response but SVR is not achieved.<\/jats:p>","DOI":"10.1093\/omcr\/omaa084","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T12:52:14Z","timestamp":1603457534000},"source":"Crossref","is-referenced-by-count":0,"title":["\u2018Double-hit\u2019 pegylated interferon-alpha successfully treats Hepatitis B and Hepatitis D co-infection"],"prefix":"10.1093","volume":"2020","author":[{"given":"Meha","family":"Bhuva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Moore","sequence":"additional","affiliation":[{"name":"Hepatology Department, Luton and Dunstable University Hospital, Luton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sambit","family":"Sen","sequence":"additional","affiliation":[{"name":"Hepatology Department, Luton and Dunstable University Hospital, Luton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"2020121213133334600_ref1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virol.2005.09.033","article-title":"Hepatitis delta virus","volume":"344","author":"Taylor","year":"2006","journal-title":"Virology"},{"volume-title":"Hepatitis D","author":"World Health Organization","key":"2020121213133334600_ref2"},{"key":"2020121213133334600_ref3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"The Lancet"},{"key":"2020121213133334600_ref4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2036.2012.04993.x","article-title":"Meta-analysis: antiviral treatment for hepatitis D","volume":"35","author":"Triantos","year":"2012","journal-title":"Aliment Pharm Ther"},{"key":"2020121213133334600_ref5","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2009.01.004","article-title":"Hepatitis D: thirty years after","volume":"50","author":"Rizzetto","year":"2009","journal-title":"J Hepatol"},{"key":"2020121213133334600_ref6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0016-5085(99)70409-9","article-title":"Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy","volume":"117","author":"Daryl","year":"1999","journal-title":"Gastroenterology"},{"key":"2020121213133334600_ref7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"2020121213133334600_ref8","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yuryaydin","year":"2018","journal-title":"J Infect Dis"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2020\/10\/omaa084\/34883186\/omaa084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2020\/10\/omaa084\/34883186\/omaa084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T18:13:40Z","timestamp":1607796820000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omaa084\/5936348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omaa084","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,10,1]]},"article-number":"omaa084"}}